Press Releases

12.06.2017

Updated Data from Phase 3 Trial of IBRANCE® (palbociclib) Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in Progression-Free Survival

12.05.2017

Bristol-Myers Squibb and Pfizer Alliance Urge People to ‘Tune in to AFib, Take Note of Stroke Risk’

12.05.2017

Pfizer Unveils 2017 ASPIRE Oncology/Hematology Clinical Research Awards Winners; Grants Totaling More than $6M in 2017

11.30.2017

Pfizer Enters into Agreement to Develop and Commercialize CRESEMBA® (isavuconazole) in China and Asia Pacific Region

11.28.2017

Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients with Pre-Treated Advanced Gastric Cancer

11.21.2017

Ground-breaking €34 million project to develop better test for liver disease

11.16.2017

Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma

11.15.2017

COMBACTE Adds a New Project to its Consortium: COMBACTE-CDI

11.15.2017

UC San Diego Center for Microbiome Innovation Announces Pfizer as Corporate Member

11.13.2017

Pfizer Names Albert Bourla Chief Operating Officer

11.10.2017

BMS-Pfizer Alliance To Unveil Real-World Data Analyses - Cost, Safety and Comparative Effectiveness Findings Associated with Oral Anticoagulants in Non-Valvular Atrial Fibrillation

11.10.2017

Pfizer Sells Its 49% Equity Share in Hisun-Pfizer Pharmaceuticals